Drug intelligence / Profile preview

VY-OZ

Development stage: Preclinical
Lead developer: Vycellix
Modality: Cell Therapies, Small Molecules
Administration: Ex Vivo (used During Cell Manufacturing Process)

Overview

VY-OZ is a proprietary small molecule developed by Vycellix as an ex vivo reagent to enhance gene transduction into cytotoxic lymphocytes and hematopoietic stem cells using viral vectors. It is designed to improve the efficiency of genetic modification protocols in cell therapy manufacturing by transiently downregulating intracellular anti-viral defense mechanisms. This enables more efficient integration of desired genes into target cells and significantly improves gene editing rates for CRISPR-based systems. The product is highly differentiated from other platforms due to its ability to reproducibly increase transduction and editing rates across multiple protocols[2][1].

Other names: VY-OZ platform

Beyond the preview

Go deeper on VY-OZ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VY-OZ.

Explore the full profile